CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals, Inc. is a biotechnology company focused on developing therapies for serious neurological conditions and cancers. The company seeks to build a portfolio of differentiated preclinical and clinical-stage drug candidates by identifying, acquiring, or in-licensing assets that offer defined biological rationales and clear regulatory pathways. Historically centered on advancing treatments for glioblastoma multiforme, including investigational compounds such as TPI 287 and Berubicin designed to cross the blood-brain barrier, the company has pivoted toward broader opportunities across neurology and oncology. Its primary target populations comprise patients diagnosed with severe neurodegenerative disorders and various oncological malignancies.

The company operates principally within the United States, maintaining its corporate headquarters in Houston, Texas. Its strategic activities encompass evaluating global asset acquisition and in-licensing opportunities across the worldwide biopharmaceutical sector. Development operations are led by an executive management team overseeing clinical, regulatory, and corporate initiatives.

Summary of the business section of CNS Pharmaceuticals's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of March 31, 2026, we had eight full time employees.”